Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trametinib Plus Tacrolimus and Methotrexate for GVHD Prophylaxis After Allogeneic HSCT
jRCT2061250095Phase 1Recruiting
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trametinib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 3 more. Primary endpoint: Number and severity of adverse events. Started May 2026; status: recruiting.
02
Drugs
trametinib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)myeloid diseases
Beyond the preview
Go deeper on jRCT2061250095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061250095.